VACCITECH (SP.ADR)/1 Total Liabilities

Latest as of March 2026: €25.66 Million EUR ≈ $30.01 Million USD

VACCITECH (SP.ADR)/1 total liabilities. Based on the latest financial reports, VACCITECH (SP.ADR)/1 (2AB) has total liabilities worth €25.66 Million EUR (≈ $30.01 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See 2AB cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.

Total Liabilities of VACCITECH (SP.ADR)/1 (2021–2025)

Total liabilities of VACCITECH (SP.ADR)/1 from 2021 to 2025. This chart illustrates how VACCITECH (SP.ADR)/1's total liabilities have evolved over time, based on quarterly financial data.

VACCITECH (SP.ADR)/1 Competitors by Total Liabilities

The table below lists competitors of VACCITECH (SP.ADR)/1 ranked by their total liabilities.

Company Country Total Liabilities
Agung Semesta Sejahtera Tbk PT
JK:TARA
Indonesia Rp42.24 Billion
MegaMD Co. Ltd
KQ:133750
Korea ₩16.86 Billion
Nova Agritech Ltd.
NSE:NOVAAGRI
India Rs-2.33 Billion
Pure Hydrogen Corporation Ltd
AU:PH2
Australia AU$10.49 Million
HYUNGJI INNOVATION & CREATIVE Co.Ltd
KQ:011080
Korea ₩25.13 Billion
Bangsaphan Barmill Public Company Limited
BK:BSBM
Thailand ฿20.36 Million
Lithium Energy Ltd
AU:LEL
Australia AU$2.64 Million
Zuleika Gold Ltd
AU:ZAG
Australia AU$2.06 Million

Liability Composition Analysis (2021–2025)

This chart breaks down VACCITECH (SP.ADR)/1's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see 2AB asset base.

Liquidity & Leverage Metrics

VACCITECH (SP.ADR)/1 Total Liabilities Ratios Explained

VACCITECH (SP.ADR)/1 total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.

Metric Value Description
Current Ratio 6.05 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.39 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.28 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how VACCITECH (SP.ADR)/1's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for VACCITECH (SP.ADR)/1 (2021–2025)

The table below shows the annual total liabilities of VACCITECH (SP.ADR)/1 from 2021 to 2025.

Year Total Liabilities Change
2025-12-31 €23.88 Million
≈ $27.91 Million
-20.92%
2024-12-31 €30.19 Million
≈ $35.30 Million
+9.75%
2023-12-31 €27.51 Million
≈ $32.16 Million
+1.88%
2022-12-31 €27.00 Million
≈ $31.57 Million
-4.08%
2021-12-31 €28.15 Million
≈ $32.91 Million
--

About VACCITECH (SP.ADR)/1

F:2AB Germany Biotechnology
Market Cap
$24.11 Million
€20.62 Million EUR
Market Cap Rank
#24866 Global
#2140 in Germany
Share Price
€0.51
Change (1 day)
+5.65%
52-Week Range
€0.45 - €1.54
All Time High
€14.00
About

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, focuses on developing immunotherapeutic drug candidates for treating auto-immune and inflammatory diseases. Its lead candidate is VTP-1000, which is in Phase 1 clinical trial to restore immune non-responsiveness to gluten in patients with celiac disease. The company is also developing VTP-300, an immunotherapeutic targetin… Read more